Notably, HER2 CAR-T cells displayed heightened efficacy against HER2-positive colorectal cancer in patient-derived tumor xenograft (PDX) models, showcasing potent immunotherapeutic potential for mCRC in metastatic xenograft mouse models. The gene discussed is ERBB2; the disease is neoplasm.